<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-26T16:03:31Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/10920" metadataPrefix="edm">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/10920</identifier><datestamp>2025-10-04T00:05:21Z</datestamp><setSpec>com_10259_4862</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_4863</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xsi:schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">
<edm:ProvidedCHO rdf:about="https://hdl.handle.net/10259/10920">
<dc:creator>Chromikova, Veronika</dc:creator>
<dc:creator>Tan, Jessica</dc:creator>
<dc:creator>Aslam, Sadaf</dc:creator>
<dc:creator>Rajabhathor, Arvind</dc:creator>
<dc:creator>Bermudez-Gonzalez, Maria</dc:creator>
<dc:creator>Ayllón Barasoain, Juan</dc:creator>
<dc:creator>Simon, Viviana</dc:creator>
<dc:creator>García Sastre, Adolfo</dc:creator>
<dc:creator>Salaun, Bruno</dc:creator>
<dc:creator>Nachbagauer, Raffael</dc:creator>
<dc:creator>Krammer, Florian</dc:creator>
<dc:date>2020-02</dc:date>
<dc:description>The stalk of the influenza virus hemagglutinin (HA) is an attractive target for antibody-based universal influenza virus vaccine development. While antibodies that target this part of the virus can be neutralizing, it has been shown in recent years that Fc receptor-mediated effector functions are of significant importance for the protective effect of anti-stalk antibodies. Several assays to measure Fc-Fc receptor interaction-based effector functions like antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis exist, but they suffer from limitations such as low throughput and high run-to-run variability. Reporter assays for antibody-dependent cellular cytotoxicity based on reporter cells that express luciferase upon engagement of human FcγRIIIa with the Fc of antigen-bound antibodies have been developed as well. These reporter assays can be used in a higher throughput setting with limited run-to-run assay variability but since they express only one Fc receptor, their biological relevance is unclear. Here we optimized an antibody-dependent cellular cytotoxicity reporter assay to measure the activity of antibodies to the conserved stalk domain of H1 hemagglutinin. The assay was then correlated to a CD107a-based degranulation assay, and a strong and significant correlation could be observed. This data suggests that the FcγRIIIa-based reporter assay is a good substitute for functional assays, especially in settings where larger sample numbers need to be analyzed.</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://hdl.handle.net/10259/10920</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>Elsevier</dc:publisher>
<dc:title>Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay</dc:title>
<dc:type>info:eu-repo/semantics/article</dc:type>
<edm:type>TEXT</edm:type>
</edm:ProvidedCHO>
<ore:Aggregation rdf:about="https://hdl.handle.net/10259/10920#aggregation">
<edm:aggregatedCHO rdf:resource="https://hdl.handle.net/10259/10920"/>
<edm:dataProvider>RIUBU. Repositorio Institucional de la Universidad de Burgos</edm:dataProvider>
<edm:isShownAt rdf:resource="https://hdl.handle.net/10259/10920"/>
<edm:isShownBy rdf:resource="https://riubu.ubu.es/bitstream/10259/10920/4/Chromikova_Vaccine_2020.pdf"/>
<edm:object rdf:resource="https://riubu.ubu.es/bitstream/10259/10920/5/Chromikova_Vaccine_2020.pdf.jpg"/>
<edm:provider>Hispana</edm:provider>
<edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
</ore:Aggregation>
<edm:WebResource rdf:about="https://riubu.ubu.es/bitstream/10259/10920/4/Chromikova_Vaccine_2020.pdf">
<edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
</edm:WebResource>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>